SynthesisMetabolomics : Official journal of the Metabolomic Society2025
Metabolomics approaches for the early detection and therapeutics: type 2 diabetes-induced diabetic kidney disease-a systematic review and meta-analysis.
Synthesis in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimDiabetic kidney disease (DKD) is a severe complication of diabetes, with early detection crucial for preventing irreversible kidney damage. Despite numerous DKD metabolite profiling studies, results remain inconsistent. This meta-analysis aims to identify consensus dysregulated metabolites as potential biomarkers for Type 2 diabetes (T2D)-induced DKD. MATERIALS AND
methodsFollowing PRISMA guidelines, a systematic review from 2014 to 2024 included human studies of T2D and DKD. Quality assessment employed the Newcastle-Ottawa Scale (NOS). Bubble plots determined predominant metabolite classes. MetaboAnalyst 5.0 facilitated pathway and enrichment analysis, while RevMan v5.4 performed meta-analysis.
resultsAmino acids were the most studied metabolite class in both T2D and DKD. Enrichment analysis highlighted glycine and serine metabolism; phenylalanine and tyrosine metabolism; and methionine metabolism as dominant pathways. Meta-analysis revealed low ornithine (-0.50 [-0.91, -0.10], p = 0.01) and high isoleucine (0.76[0.50, 1.03], p < 0.00001) concentrations associated with T2D. Conversely, lower methionine (-0.32 [-0.57, -0.08), p = 0.01), tyrosine (-0.73 [-1.28, -0.17], p = 0.01), and valine (-2.32 [-2.99, -1.66], p = 0.009) levels were associated with DKD. Correlation analysis revealed associations between phenylalanine, tyrosine, and serine with albumin and creatinine levels in T2D but not in DKD.
conclusionsThese identified metabolites hold potential as early markers for T2D-induced DKD. However, the use of these metabolites for clinical purposes requires experimental validation and clinical trials.
Indexed as
Identifiers
41175152What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.